How Big Pharma Controls Medical Education
April 21, 2025 · Frisian News
Pharmaceutical companies spend billions funding medical schools, professorships, and student scholarships, shaping what doctors learn about drugs. Medical schools have become dependent on this money while maintaining the fiction of independence.
A medical student at a major Dutch university attends a lecture on hypertension treatment. The professor presenting the material holds a research chair funded entirely by a manufacturer of blood pressure drugs. The slides emphasize this company's product over generic alternatives. No one in the room questions this arrangement, because it has become normal. The money flows in quietly, and medical education shifts with it.
Pharmaceutical firms donate roughly 500 million euros annually to European medical schools, research centers, and doctor training programs. They fund individual professorships, scholarships, and continuing education courses. Drug companies also sponsor the conferences where doctors gather to learn new treatment methods. In return, they gain access to young minds during the most formative years of medical training. A student who learns about a drug from a company-sponsored professor is more likely to prescribe it later as a doctor. The companies know this. They have calculated the return on investment.
Medical schools claim independence from industry influence, yet they cannot function without the money. Universities cut budgets for basic research while pharmaceutical funding fills the gap. Professors accept industry donations to support their work. Students receive scholarships with no strings attached, or so the schools insist. The result is a system where pharma money props up the entire structure of medical education. Remove it, and many schools would struggle to keep the lights on. No institution in this position can truly bite the hand that feeds it.
The conflicts of interest run deeper than most patients understand. A doctor trained by industry-sponsored professors learns to see expensive patented drugs as standard care. Teaching about cost-effective generics or non-drug treatments gets less attention and less funding. Medical schools produce graduates who reflexively reach for the most profitable medications, not always the most appropriate ones. This is not a conspiracy hatched in boardrooms. It is a system that rewards itself and reproduces itself across generations of doctors.
Some medical schools in Scandinavia and parts of Switzerland have tightened restrictions on pharmaceutical sponsorship. They found other funding sources and maintained academic freedom. But most European universities have not made this choice. They prefer the money. Until medical schools stop depending on drug company cash, doctors will continue to learn medicine from professors with conflicts of interest. The patients are the ones who pay the price.
In medyske studinten oan in grôte Nederlânske universiteit folget in college oer behanneling fan hege bloeddruk. De professor dy't it materiaal presintearret, hâldt in learstoele dy't hielendal troch in fabrikant fan bloeddrukferlegende middels finansiere wurdt. De slides beklamje it produkt fan dit bedriuw boppe generike altearnativen. Nimmen yn it klaslokaal stelt spytsjes by dizze regeling, om't it normaal is wurden. It jild stroomt yn stilte, en de medyske ûnderwiis ferskuovet dermei.
Farmaseútske bedriuwen jouwe jierliks sa'n 500 miljoen euro oan Europeeske medyske skoallen, ûndersykssintra en doktersopleidspaogramma's. Se finansjearre yndividuele learstoelen, boarzen en fierlegginkskursussen. Medysinefabrikanten sponsorje ek de konferinsjes wêr dokters byienkomme om nije behannelingsmethoden te learen. Yn útwikseling dêrfoar krijt se tagong ta jonge geastfen yn 'e meast formative jierren fan medyske training. In studinnt dy't oer in medisine learet fan in troch bedriuwen sponsore professor sil it letter as dokter wierskynliker foarskreauw. De bedriuwen wite dit. Se hawwe de ynvestearringsomtsjinst berekkene.
Medyske skoallen stelle ûnôfhinklikheid fan industriëlle bydragen, mar se kinne net funktsjonearre sûnder it jild. Universiteiten snoeie begrûtsjes foar basisûndersyk, wylst farmaseútske finansiering de gat opfult. Professoren akseptearre industriëdobaasjez om har wurk te stypjen. Studinter krije boarzen sûnder foarutzettingen, of sa stelle de skoallen it. It resultaat is in systeem wêryn farmajild de heule struktuer fan medyske ûnderwiis stypet. Fuort jo it, en in protte skoallen soe muoilte hawwe om de ljochten oan te hâlden. Gjin ynstelling yn dizze posysje kin echt de hân dy't har fydt byt.
De belangenkonfliken gean djippeŕ dan de measte pasjinten begripe. In dokter dy't troch bedriuwen sponsore professoren is oplaat, learet djoere merkmedisinen as standaartzakehâldingszakenhâldingssakehâldingssakehâlding te sjen. Ûnderwiis oer kosteneffeksyf generike medisinen of net-medisinebehandeling krijt minus omtinken en minus finansiering. Medyske skoallen produsearje ôfstudearren dy't automats nei de winsgjefte medisinen gripelje, net altyd de meast toepasselijke. Dit is gjin komplosje dy't yn direktiekamers wurdt beraamd. It is in systeem dat himsels belóant en himsels fierplant oer generaasjes dokters.
Some medyske skoallen yn Skandinaio en dielen fan Switserland hawwe de restricksjes op farmaseútske sponsoring oanskierd. Se fûnen oare finansieringsbronnen en hâlden akademyske frijheid. Mar de measte Europeske universiteiten hawwe dizze kar net makke. Se jûn de foarkar oan it jild. Oant medyske skoallen net mear ôfhinklik binne fan farmajild, bliuwe dokters medisine learne fan professoren mei belangenkonfliken. De pasjinten binne dyjingen dy't de priis betelje.
Published April 21, 2025 · Frisian News · Ljouwert, Fryslân